TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A prospective study found that women in the highest exposure groups for PFOA and PFOS had higher rates of estrogen receptor-negative breast cancer than women in the lowest groups. The findings show an association, not proof that the chemicals cause cancer; a review of seven studies also supported an association for PFOA, but not clearly for PFOS.
A prospective study has linked higher exposure to two widely studied PFAS chemicals, PFOA and PFOS, with a higher risk of estrogen receptor-negative (ER-negative) breast cancer, a subtype that is generally more aggressive. The results, reported by researchers led by Alexandra J. White of the U.S. National Institute of Environmental Health Sciences, show an association; they do not establish that PFAS exposure caused the cancers.
In the study, women in the highest exposure quartile for PFOA had a higher risk of ER-negative breast cancer than women in the lowest quartile (hazard ratio 1.67; 95% confidence interval 1.10 to 2.53). For PFOS, the corresponding hazard ratio was 1.93 (95% confidence interval 1.15 to 3.22). These estimates compare groups within this study and do not show an individual’s absolute chance of developing cancer.
The researchers also conducted a meta-analysis of seven studies. It found an association between PFOA and ER-negative breast cancer (relative risk 1.30; 95% confidence interval 1.05 to 1.62). The estimate for PFOS was smaller and its confidence interval included no association (relative risk 1.20; 95% confidence interval 0.91 to 1.58), making that pooled result less conclusive.
The main analysis drew on the Sister Study, a U.S. and Puerto Rico cohort of 50,884 women who had a sister diagnosed with breast cancer. Researchers included 1,609 women who developed breast cancer and a comparison sample of 2,269 women. PFAS were measured in blood collected before diagnosis, and the team quantified 17 chemicals. Median follow-up was 5.9 years in the case group and 9.7 years in the comparison group. Researchers oversampled women with ER-negative tumors because this subtype is less common and harder to study.
Why ER-Negative Findings Matter
ER-negative tumors do not have estrogen receptors, and the researchers described them as generally more aggressive. The study authors said there are relatively few established risk factors for this subtype, making possible environmental contributors a subject of public health interest. The results add to evidence on whether exposure to certain persistent chemicals may be associated with a specific breast cancer subtype.
White told MedPage Today that many factors contribute to breast cancer risk and said PFAS may be one contributor specifically to ER-negative disease. She said people concerned about exposure could reasonably take steps to reduce sources such as contaminated water. That comment is not evidence that reducing exposure prevents cancer, and the study did not test an exposure-reduction intervention.
The findings also matter because the compounds examined have been phased out from industry and largely replaced by other PFAS, according to the researchers. They said many people still have measurable levels of the older chemicals in their bodies. The study therefore supports further research into both the health effects of these legacy compounds and the replacements now in use.
Products Worth Considering
Levoit Vital 100S-P Air Purifier with Washable Pre-Filter
Hyperice Hypervolt Go 3 Portable Percussion Massage Gun with Carry Case
Philips Sonicare 5950 Rechargeable Electric Toothbrush with 2 Brush Heads, Pink
As an affiliate, we earn on qualifying purchases.
How Researchers Tested PFAS Exposure
PFAS, short for per- and polyfluoroalkyl substances, are a broad group of chemicals often called “forever chemicals” because some persist in the environment and in the body. This study focused on measured concentrations of particular PFAS rather than treating the entire chemical group as one exposure. Its blood samples were collected before breast cancer diagnoses, helping researchers examine exposure ahead of the outcome rather than relying only on participants’ recollections after diagnosis.
The team reported that positive associations were generally concentrated in hormone receptor-negative tumors. It suggested that nonhormonal processes could be relevant, including epigenetic changes or immunosuppression, while noting that these are possible mechanisms rather than demonstrated explanations. Other results were mixed: one PFAS had an inverse association with ER-negative tumors, while a possible link between another chemical and that subtype did not reach statistical significance. For overall breast cancer incidence, most measured PFAS showed negligible associations.
“Our findings suggest these chemicals may be one contributor to ER-negative breast cancer risk specifically.”
— Alexandra J. White, speaking to MedPage Today
What the Association Cannot Show
The study does not establish that PFOA or PFOS caused breast cancer, nor does it show how much changing an individual’s exposure would alter risk. An observational study can identify patterns but cannot, by itself, rule out other explanations. The Sister Study participants also all had a sister with breast cancer, so the results may not apply in the same way to every population.
Some estimates were imprecise, particularly in the meta-analysis for PFOS, whose confidence interval included no association. The research also found results that differed by chemical and tumor subtype. It remains unclear which biological pathways, if any, explain the observed patterns, how exposure levels relate to risk outside the study groups, and whether replacement PFAS have similar or different health effects.
Research on Replacement Chemicals
The authors called for more study of the health effects of PFAS now used as replacements for phased-out compounds. Future research can test whether the reported subtype-specific associations appear in other populations and clarify how exposure timing, level and different chemicals relate to risk. The report does not announce a planned follow-up study or a new regulatory action.
For now, the finding is best understood as evidence of an association that merits further investigation, not a basis for predicting an individual’s diagnosis. White said reducing exposure from sources such as contaminated water would be reasonable for people who have concerns, but the study did not assess a specific prevention strategy. Further results will be needed to determine whether the observed links are consistent and what they mean for public health.
Key Questions
Which chemicals were linked to ER-negative breast cancer?
The study found higher risk among women in the highest exposure quartiles for PFOA and PFOS compared with those in the lowest quartiles. The results describe associations and do not prove either chemical caused cancer.
Does this study prove that PFAS cause breast cancer?
No. This was an observational study. It found that exposure levels and ER-negative breast cancer occurred together more often in some comparisons, but it cannot establish cause and effect or rule out all other explanations.
What does ER-negative breast cancer mean?
ER-negative breast cancer refers to tumors that lack estrogen receptors. The study authors described these tumors as generally more aggressive and said they have fewer established risk factors than some other breast cancer types.
Did the study find a link with all breast cancers?
The clearest reported associations were for ER-negative tumors. For overall breast cancer incidence, the researchers reported negligible associations for most PFAS measured, with some other results described as suggestive rather than conclusive.
What should readers know about PFAS exposure now?
The study does not provide an individual risk estimate or test whether reducing exposure prevents cancer. White told MedPage Today that reducing exposure from sources such as contaminated water would be reasonable for people concerned, while researchers called for more work, especially on replacement PFAS.
Source: medpagetoday.com
